23andMe News

23andMe | 8-K: Kathy Hibbs Retires as 23andMe's Chief Administrative Officer

May 24 16:08 ET

23andMe | 8-K: 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

May 23 16:14 ET

23andMe | 8-K: Current report

May 10 16:19 ET

23andMe | 8-K: 23andMe Announces CEO's Intention to Pursue a Potential Take-Private

Apr 18 08:11 ET

23andMe | 8-K: 23andMe CAO Kathy Hibbs Retires, Guy Chayoun Steps In

Mar 29 12:47 ET

23andMe | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 22 17:09 ET

23andMe | 8-K: 23andMe Reports Third Quarter Fiscal 2024 Financial Results

Feb 7 16:07 ET

23andMe | 8-K: 23andme Announces Fda Clearance of Ind Application for Its Dual Mechanism Antibody, 23me-01473, Targeting Ulbp6

Jan 31 07:51 ET

23andMe | 8-K: 23andMe Posted The Investor Presentation

Jan 8 00:00 ET

23andMe | 8-K/A: 23andMe Says Some Profiles Were Accessed in Cybersecurity Breach and Has Retained Third-Party Forensic Experts to Assist in an Investigation of the Cause and Scope of the Incident (Amendment)

Dec 1, 2023 16:06 ET

23andMe | 8-K: Current report

Nov 13, 2023 16:06 ET

23andMe | 8-K: 23andMe Reports Second Quarter Fiscal 2024 Financial Results

Nov 8, 2023 16:29 ET

23andMe | 8-K: 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

Nov 6, 2023 08:15 ET

23andMe | 8-K: 23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

Oct 30, 2023 16:05 ET

23andMe | 8-K: Paul Johnson, The Vice President, Europe, And a Named Executive Officer of 23andMe Holding Co., Tendered His Resignation to the Company

Oct 27, 2023 16:06 ET

23andMe | 8-K: 23andme Says Some Profiles Were Accessed in Cybersecurity Breach and Has Retained Third-Party Forensic Experts to Assist in an Investigation of the Cause and Scope of the Incident

Oct 10, 2023 16:17 ET

23andMe | 8-K: 23andMe Holding Co. approved the grant of annual long-term equity awards for the fiscal year ending March 31, 2024

Sep 19, 2023 16:06 ET

23andMe | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Sep 15, 2023 16:06 ET

23andMe | 8-K: Poll Results of 2023 Stockholders Meeting

Sep 11, 2023 16:06 ET

23andMe | 8-K: 23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Aug 31, 2023 17:35 ET